BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Aditxt, Inc. ADTX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3,195
▼ 97.6% vs FY2024
EPS · FY25
$-1153.83
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1183.4%
Net margin · FY25
-1349028.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3,195.00
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 1349028 cents on every revenue dollar this year.
Per share
USD -1153.83
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1183.4%
Return on equity, FY2025
ROE
Operating margin-612542.2%
Net margin-1349028.2%
Return on assets-177.1%
Each USD of equity lost 1183 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−84.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.5M
total assets, end of FY2025
Total assetsUSD 16.5M
EquityUSD 5.6M
CashUSD 3.2M
Current ratio0.31×
Equity funds 34% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1153.83
−22147415.22
−27038.26
−595.60
−121.18
−1.33
−1.52
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−1183.4
−455.2
−307.6
−359.4
−437.6
−224.3
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed